Image source: Shutterstock

Highlights

  • BUY Rating with 30.18% upside potential based on target price of AUD 312.99

  • FDA approval of ANDEMBRY® opens significant commercial opportunity in the U.S.

  • Global expansion of ANDEMBRY with prior approvals across six major markets

  • Appointment of Cameron Price adds governance depth to CSL’s board

CSL Limited (ASX:CSL) has garnered renewed investor confidence, with analysts issuing BUY recommendations and assigning a target price of AUD 312.99, suggesting a 30.18% upside potential. This follows key developments including the FDA approval of ANDEMBRY®, a pioneering hereditary angioedema (HAE) treatment, and the appointment of Mr. Cameron Price as an Independent Non-Executive Director, effective October 2025.

These developments underline CSL’s strategic positioning in the global biopharmaceutical space and reinforce analyst optimism reflected in the company’s rating of 1.94 (BUY) and a long-term growth (LTG) outlook of 13.51%.

ANDEMBRY®: Game-Changing FDA Approval

CSL recently announced that the U.S. Food and Drug Administration (FDA) has approved ANDEMBRY® for immediate launch in the United States. ANDEMBRY® is the first and only prophylactic treatment for hereditary angioedema (HAE) that targets factor XIIa, offering once-monthly dosing from initiation and delivered via a convenient autoinjector.

In clinical trials, the therapy achieved:

  • >99% reduction in median HAE attack frequency

  • 89.2% mean reduction in attacks compared to placebo

  • Proven efficacy in both adult and pediatric patients aged 12 and older

This approval builds on prior regulatory wins in Australia, the UK, EU, Japan, Switzerland, and the UAE, expanding CSL’s commercial reach and product portfolio. The product will be launched in the U.S. market by the end of June 2025 through CSL’s specialty pharmacy network, significantly enhancing revenue potential.

Leadership Strengthened with Cameron Price Appointment

CSL also announced the appointment of Mr. Cameron Price as Independent Non-Executive Director, effective 1 October 2025. Mr. Price brings an extensive background in law, governance, and risk management. He recently retired as General Counsel & Chief Risk Officer at the Future Fund, which oversees over $264 billion in sovereign investments.

His strategic experience includes:

  • Over a decade leading legal and compliance operations at the Future Fund

  • Former partner and board member at Allens law firm

  • Specialisation in M&A, equity capital markets, and corporate governance

His appointment is expected to enhance board oversight, governance rigour, and strategic vision during a crucial expansion phase for CSL.

Analyst Sentiment Remains Upbeat

Two leading analysts have offered supportive ratings:

  • Bell Potter Securities: BUY rating with a AUD 305.00 target (+26.97% upside)

  • Wilsons: Marketweight with a target of AUD 250.00, still reflecting a modest 4.08% upside